23:43 , May 31, 2018 |  BC Innovations  |  Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
19:55 , Oct 13, 2017 |  BioCentury  |  Regulation

Expanding the HAE tool kit

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency. Two subcutaneous prophylactics that have completed Phase...
07:00 , May 29, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Bradykinin receptor Rat and in vitro studies identified dynorphin A analogs that antagonize bradykinin receptors and could be useful for treating chronic pain. In...
07:00 , Sep 8, 2004 |  BC Extra  |  Clinical News

Jerini starts HAE Phase III

Jerini (Berlin, Germany) began the double-blind, placebo-controlled Phase III FAST 1 trial of its subcutaneous Icatibant in more than 50 patients in the U.S. and Canada with hereditary angioedema (HAE). The company plans to start...
07:00 , Jul 26, 2004 |  BC Week In Review  |  Clinical News

Icatibant regulatory update

FDA granted Fast Track designation for Icatibant, a bradykinin receptor antagonist, to treat hereditary angioedema (HAE). Jerini AG , Berlin, Germany   Product: Icatibant   Business: Cardiovascular  ...
07:00 , Jul 12, 2004 |  BC Week In Review  |  Clinical News

Icatibant regulatory update

FDA granted Orphan Drug designation to Icatibant, a bradykinin receptor antagonist, to treat edema in patients with severe burns. Jerini AG , Berlin, Germany   Product: Icatibant   Business: Dermatology  ...
08:00 , Dec 2, 2003 |  BC Extra  |  Clinical News

Jerini Phase IIa liver cirrhosis data

Jerini (Berlin, Germany) said that in a cross-over, double-blind, placebo-controlled Swiss Phase IIa trial in 8 healthy volunteers and 8 patients with refractory ascites in liver cirrhosis, Icatibant ( JE049 ) met the primary endpoints...
08:00 , Feb 17, 2003 |  BC Week In Review  |  Clinical News

Icatibant: Phase II

Jerini began a European Phase II trial in 80 patients. Icatibant was licensed from AVE and has Orphan Drug designation in Europe. The compound is in a Phase IIa trial to treat late-stage liver cirrhosis....
08:00 , Feb 17, 2003 |  BioCentury  |  Finance

Ebb & Flow

Market watchers don't expect a flood of big biotech takeouts similar to JNJ-SCIO. Instead, they expect an increase in activity for the smaller names that are unable to tap the market. "On the small cap...
08:00 , Nov 4, 2002 |  BC Week In Review  |  Clinical News

Icatibant: Phase IIa

Jerini began a European Phase IIa trial of Icatibant in patients with late-stage liver cirrhosis and hepato-renal syndrome. Icatibant was licensed from AVE. Jerini AG , Berlin, Germany   Aventis S.A. (AVE), Strasbourg, France  ...